1. Home
  2. KVUE

as 11-20-2024 4:00pm EST

$
-
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Consumer Discretionary

Specialty Chemicals

Nasdaq

Kenvue is the world's largest pure-play consumer health company by sales, generating $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio includes a wide array of some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and ever-changing consumer preferences, many of Kenvue's brands are the global leader in their respective segment thanks to their strong brand power.

Founded: 2022 Country:
United States
United States
Employees: N/A City: SKILLMAN
Market Cap: 45.7B IPO Year: 2023
Target Price: $22.64 AVG Volume (30 days): 15.3M
Analyst Decision: Buy Number of Analysts: 12
Dividend Yield:
3.46%
Dividend Payout Frequency: Quarterly
EPS: 0.55 EPS Growth: -41.30
52 Week Low/High: $17.67 - $24.13 Next Earning Date: 11-07-2024
Revenue: $15,459,000,000 Revenue Growth: -0.55%
Revenue Growth (this year): 3.35% Revenue Growth (next year): 3.50%

KVUE Daily Stock ML Predictions

Share on Social Networks: